查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1212544

抗高血压药物的全球市场

Anti-Hypertensive Drugs
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 326 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

抗高血压药物的全球市场2030年将达到297亿美元

在COVID-19后改变的商务环境中，2022年239亿美元的抗高血压药物的全球市场在2030年前将修正达到297亿美元的规模，在分析期间2022-2030年间将以2.8％的年复合成长率增长。本报告所分析的市场区隔之一的钙拮抗剂将记录年复合成长率3.2％，到分析期间结束时将达到72亿美元。考虑疫情后的復苏，ACE抑制剂市场区隔今后8年的年复合成长率将修正为3.7％。

美国市场估算为65亿美元，中国预测将以年复合成长率4.7％增长。

关于美国的降压剂市场，2022年达到65亿美元。作为世界第2大经济大国的中国，在2022年到2030年间将以年复合成长率4.7％在2030年前将修正达到58亿美元的市场规模。其他热门的地区市场有日本和加拿大，从2022年到2030各将以1.5％和2.3％的速度成长。在欧洲市场中，德国以年复合成长率1.9％成长。在亚太地区，澳洲，印度，韩国等国家在2030年前将修正达到38亿美元。

调查对像企业范例

  • Actelion Pharmaceuticals Ltd.
  • AstraZeneca PLC
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Daiichi Sankyo Co., Ltd.
  • Johnson & Johnson
  • Lupin Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Novartis International AG
  • Pfizer, Inc.
  • Sanofi
  • Takeda Pharmaceutical Co., Ltd.

目录

第1章 调查手法

第2章 摘要整理

  • 市场概要
  • 主要企业
  • 市场趋势与推动因素
  • 全球市场预测

第3章 市场分析

  • 美国
  • 加拿大
  • 日本
  • 中国
  • 欧洲
  • 法国
  • 德国
  • 义大利
  • 英国
  • 西班牙
  • 俄罗斯
  • 其他欧洲
  • 亚太地区
  • 澳洲
  • 印度
  • 韩国
  • 其他亚太地区
  • 南美
  • 阿根廷
  • 巴西
  • 墨西哥
  • 其他南美国家
  • 中东
  • 伊朗
  • 以色列
  • 沙乌地阿拉伯
  • 阿拉伯联合大公国
  • 其他中东
  • 非洲

第4章 竞争

简介目录
Product Code: MCP-6021

What`s New for 2023?

»Special coverage on Russia-Ukraine war; global inflation; easing of "zero-Covid" policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.

»Global competitiveness and key competitor percentage market shares

» Market presence across multiple geographies - Strong/Active/Niche/Trivial

»Online interactive peer-to-peer collaborative bespoke updates

»Access to our digital archives and MarketGlass Research Platform

»Complimentary updates for one year

Looking Ahead to 2023

The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet. Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China's already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Global Anti-Hypertensive Drugs Market to Reach $29.7 Billion by 2030

In the changed post COVID-19 business landscape, the global market for Anti-Hypertensive Drugs estimated at US$23.9 Billion in the year 2022, is projected to reach a revised size of US$29.7 Billion by 2030, growing at a CAGR of 2.8% over the analysis period 2022-2030. Calcium Channel Blockers, one of the segments analyzed in the report, is projected to record a 3.2% CAGR and reach US$7.2 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the ACE Inhibitors segment is readjusted to a revised 3.7% CAGR for the next 8-year period.

The U.S. Market is Estimated at $6.5 Billion, While China is Forecast to Grow at 4.7% CAGR

The Anti-Hypertensive Drugs market in the U.S. is estimated at US$6.5 Billion in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$5.8 Billion by the year 2030 trailing a CAGR of 4.7% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 1.5% and 2.3% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 1.9% CAGR. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$3.8 Billion by the year 2030.

Select Competitors (Total 143 Featured):

  • Actelion Pharmaceuticals Ltd.
  • AstraZeneca PLC
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Daiichi Sankyo Co., Ltd.
  • Johnson & Johnson
  • Lupin Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Novartis International AG
  • Pfizer, Inc.
  • Sanofi
  • Takeda Pharmaceutical Co., Ltd.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Anti-Hypertensive Drugs - Global Key Competitors Percentage Market Share in 2022 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
    • Impact of Covid-19 and a Looming Global Recession
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Anti-Hypertensive Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Anti-Hypertensive Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 3: World 18-Year Perspective for Anti-Hypertensive Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2023 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Diuretics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Diuretics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 6: World 18-Year Perspective for Diuretics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for ACE Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 8: World Historic Review for ACE Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 9: World 18-Year Perspective for ACE Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Calcium Channel Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Calcium Channel Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 12: World 18-Year Perspective for Calcium Channel Blockers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 15: World 18-Year Perspective for Other Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Beta-Adrenergic Blocker by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 17: World Historic Review for Beta-Adrenergic Blocker by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 18: World 18-Year Perspective for Beta-Adrenergic Blocker by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Vasodilators by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 20: World Historic Review for Vasodilators by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 21: World 18-Year Perspective for Vasodilators by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030
    • TABLE 22: World Anti-Hypertensive Drugs Market Analysis of Annual Sales in US$ Million for Years 2012 through 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Anti-Hypertensive Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
    • TABLE 23: USA Recent Past, Current & Future Analysis for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 25: USA 18-Year Perspective for Anti-Hypertensive Drugs by Type - Percentage Breakdown of Value Sales for Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types for the Years 2012, 2023 & 2030
  • CANADA
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 28: Canada 18-Year Perspective for Anti-Hypertensive Drugs by Type - Percentage Breakdown of Value Sales for Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types for the Years 2012, 2023 & 2030
  • JAPAN
    • Anti-Hypertensive Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
    • TABLE 29: Japan Recent Past, Current & Future Analysis for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 30: Japan Historic Review for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 31: Japan 18-Year Perspective for Anti-Hypertensive Drugs by Type - Percentage Breakdown of Value Sales for Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types for the Years 2012, 2023 & 2030
  • CHINA
    • Anti-Hypertensive Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
    • TABLE 32: China Recent Past, Current & Future Analysis for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 33: China Historic Review for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 34: China 18-Year Perspective for Anti-Hypertensive Drugs by Type - Percentage Breakdown of Value Sales for Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types for the Years 2012, 2023 & 2030
  • EUROPE
    • Anti-Hypertensive Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
    • TABLE 35: Europe Recent Past, Current & Future Analysis for Anti-Hypertensive Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 36: Europe Historic Review for Anti-Hypertensive Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 37: Europe 18-Year Perspective for Anti-Hypertensive Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2023 & 2030
    • TABLE 38: Europe Recent Past, Current & Future Analysis for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 39: Europe Historic Review for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 40: Europe 18-Year Perspective for Anti-Hypertensive Drugs by Type - Percentage Breakdown of Value Sales for Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types for the Years 2012, 2023 & 2030
  • FRANCE
    • Anti-Hypertensive Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
    • TABLE 41: France Recent Past, Current & Future Analysis for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 42: France Historic Review for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 43: France 18-Year Perspective for Anti-Hypertensive Drugs by Type - Percentage Breakdown of Value Sales for Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types for the Years 2012, 2023 & 2030
  • GERMANY
    • Anti-Hypertensive Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
    • TABLE 44: Germany Recent Past, Current & Future Analysis for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 45: Germany Historic Review for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 46: Germany 18-Year Perspective for Anti-Hypertensive Drugs by Type - Percentage Breakdown of Value Sales for Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types for the Years 2012, 2023 & 2030
  • ITALY
    • TABLE 47: Italy Recent Past, Current & Future Analysis for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 48: Italy Historic Review for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 49: Italy 18-Year Perspective for Anti-Hypertensive Drugs by Type - Percentage Breakdown of Value Sales for Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types for the Years 2012, 2023 & 2030
  • UNITED KINGDOM
    • Anti-Hypertensive Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
    • TABLE 50: UK Recent Past, Current & Future Analysis for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 51: UK Historic Review for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 52: UK 18-Year Perspective for Anti-Hypertensive Drugs by Type - Percentage Breakdown of Value Sales for Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types for the Years 2012, 2023 & 2030
  • SPAIN
    • TABLE 53: Spain Recent Past, Current & Future Analysis for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 54: Spain Historic Review for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 55: Spain 18-Year Perspective for Anti-Hypertensive Drugs by Type - Percentage Breakdown of Value Sales for Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types for the Years 2012, 2023 & 2030
  • RUSSIA
    • TABLE 56: Russia Recent Past, Current & Future Analysis for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 57: Russia Historic Review for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 58: Russia 18-Year Perspective for Anti-Hypertensive Drugs by Type - Percentage Breakdown of Value Sales for Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types for the Years 2012, 2023 & 2030
  • REST OF EUROPE
    • TABLE 59: Rest of Europe Recent Past, Current & Future Analysis for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 60: Rest of Europe Historic Review for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 61: Rest of Europe 18-Year Perspective for Anti-Hypertensive Drugs by Type - Percentage Breakdown of Value Sales for Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types for the Years 2012, 2023 & 2030
  • ASIA-PACIFIC
    • Anti-Hypertensive Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
    • TABLE 62: Asia-Pacific Recent Past, Current & Future Analysis for Anti-Hypertensive Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 63: Asia-Pacific Historic Review for Anti-Hypertensive Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 64: Asia-Pacific 18-Year Perspective for Anti-Hypertensive Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2023 & 2030
    • TABLE 65: Asia-Pacific Recent Past, Current & Future Analysis for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 66: Asia-Pacific Historic Review for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 67: Asia-Pacific 18-Year Perspective for Anti-Hypertensive Drugs by Type - Percentage Breakdown of Value Sales for Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types for the Years 2012, 2023 & 2030
  • AUSTRALIA
    • Anti-Hypertensive Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2023 (E)
    • TABLE 68: Australia Recent Past, Current & Future Analysis for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 69: Australia Historic Review for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 70: Australia 18-Year Perspective for Anti-Hypertensive Drugs by Type - Percentage Breakdown of Value Sales for Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types for the Years 2012, 2023 & 2030
  • INDIA
    • Anti-Hypertensive Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2023 (E)
    • TABLE 71: India Recent Past, Current & Future Analysis for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 72: India Historic Review for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 73: India 18-Year Perspective for Anti-Hypertensive Drugs by Type - Percentage Breakdown of Value Sales for Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types for the Years 2012, 2023 & 2030
  • SOUTH KOREA
    • TABLE 74: South Korea Recent Past, Current & Future Analysis for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 75: South Korea Historic Review for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 76: South Korea 18-Year Perspective for Anti-Hypertensive Drugs by Type - Percentage Breakdown of Value Sales for Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types for the Years 2012, 2023 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 77: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 78: Rest of Asia-Pacific Historic Review for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 79: Rest of Asia-Pacific 18-Year Perspective for Anti-Hypertensive Drugs by Type - Percentage Breakdown of Value Sales for Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types for the Years 2012, 2023 & 2030
  • LATIN AMERICA
    • Anti-Hypertensive Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2023 (E)
    • TABLE 80: Latin America Recent Past, Current & Future Analysis for Anti-Hypertensive Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 81: Latin America Historic Review for Anti-Hypertensive Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 82: Latin America 18-Year Perspective for Anti-Hypertensive Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2012, 2023 & 2030
    • TABLE 83: Latin America Recent Past, Current & Future Analysis for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 84: Latin America Historic Review for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 85: Latin America 18-Year Perspective for Anti-Hypertensive Drugs by Type - Percentage Breakdown of Value Sales for Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types for the Years 2012, 2023 & 2030
  • ARGENTINA
    • TABLE 86: Argentina Recent Past, Current & Future Analysis for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 87: Argentina Historic Review for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 88: Argentina 18-Year Perspective for Anti-Hypertensive Drugs by Type - Percentage Breakdown of Value Sales for Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types for the Years 2012, 2023 & 2030
  • BRAZIL
    • TABLE 89: Brazil Recent Past, Current & Future Analysis for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 90: Brazil Historic Review for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 91: Brazil 18-Year Perspective for Anti-Hypertensive Drugs by Type - Percentage Breakdown of Value Sales for Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types for the Years 2012, 2023 & 2030
  • MEXICO
    • TABLE 92: Mexico Recent Past, Current & Future Analysis for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 93: Mexico Historic Review for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 94: Mexico 18-Year Perspective for Anti-Hypertensive Drugs by Type - Percentage Breakdown of Value Sales for Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types for the Years 2012, 2023 & 2030
  • REST OF LATIN AMERICA
    • TABLE 95: Rest of Latin America Recent Past, Current & Future Analysis for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 96: Rest of Latin America Historic Review for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 97: Rest of Latin America 18-Year Perspective for Anti-Hypertensive Drugs by Type - Percentage Breakdown of Value Sales for Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types for the Years 2012, 2023 & 2030
  • MIDDLE EAST
    • Anti-Hypertensive Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2023 (E)
    • TABLE 98: Middle East Recent Past, Current & Future Analysis for Anti-Hypertensive Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 99: Middle East Historic Review for Anti-Hypertensive Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 100: Middle East 18-Year Perspective for Anti-Hypertensive Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2012, 2023 & 2030
    • TABLE 101: Middle East Recent Past, Current & Future Analysis for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 102: Middle East Historic Review for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 103: Middle East 18-Year Perspective for Anti-Hypertensive Drugs by Type - Percentage Breakdown of Value Sales for Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types for the Years 2012, 2023 & 2030
  • IRAN
    • TABLE 104: Iran Recent Past, Current & Future Analysis for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 105: Iran Historic Review for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 106: Iran 18-Year Perspective for Anti-Hypertensive Drugs by Type - Percentage Breakdown of Value Sales for Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types for the Years 2012, 2023 & 2030
  • ISRAEL
    • TABLE 107: Israel Recent Past, Current & Future Analysis for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 108: Israel Historic Review for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 109: Israel 18-Year Perspective for Anti-Hypertensive Drugs by Type - Percentage Breakdown of Value Sales for Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types for the Years 2012, 2023 & 2030
  • SAUDI ARABIA
    • TABLE 110: Saudi Arabia Recent Past, Current & Future Analysis for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 111: Saudi Arabia Historic Review for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 112: Saudi Arabia 18-Year Perspective for Anti-Hypertensive Drugs by Type - Percentage Breakdown of Value Sales for Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types for the Years 2012, 2023 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 113: UAE Recent Past, Current & Future Analysis for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 114: UAE Historic Review for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 115: UAE 18-Year Perspective for Anti-Hypertensive Drugs by Type - Percentage Breakdown of Value Sales for Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types for the Years 2012, 2023 & 2030
  • REST OF MIDDLE EAST
    • TABLE 116: Rest of Middle East Recent Past, Current & Future Analysis for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 117: Rest of Middle East Historic Review for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 118: Rest of Middle East 18-Year Perspective for Anti-Hypertensive Drugs by Type - Percentage Breakdown of Value Sales for Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types for the Years 2012, 2023 & 2030
  • AFRICA
    • Anti-Hypertensive Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2023 (E)
    • TABLE 119: Africa Recent Past, Current & Future Analysis for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 120: Africa Historic Review for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
    • TABLE 121: Africa 18-Year Perspective for Anti-Hypertensive Drugs by Type - Percentage Breakdown of Value Sales for Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types for the Years 2012, 2023 & 2030

IV. COMPETITION